Research Framework: Biochemically Produced Antimicrobial Liquid – Investigation, Production and Global Disseminationbrication, and Global Dissemination

This research framework describes the scientific investigation, production and global dissemination of a specially prepared liquid with antimicrobial properties. The project is conducted under the scientific leadership of the CIRAS Center for Health and forms a central component of the long-term research agenda of Dr. rer. nat. Uwe Häcker.

1. Initiative Synopsis

A terminological clarification is essential from the outset: the substance at the centre of this project is not water in the generally understood sense – neither a conventional aqueous solution nor a simple electrolysis product. It is, rather, a specially prepared liquid that has been scientifically characterised over several years, whose source form and process management differ fundamentally from conventional electrochemical activation procedures.

The project adopts a transdisciplinary approach, integrating perspectives from biochemistry, microbiology, environmental health and systems theory. It is embedded within CIRAS’s overarching research programme on sustainable global solutions in the field of infection prevention.

Domain integration: Transdisciplinary alignment across CIRAS sectors: Health, Economics, Environment, and Infrastructure.

Geographical scope: Primary production sites in Tirana, Elbasan, and Durres (Albania); distribution hubs in the United Arab Emirates; progressive expansion to the Balkan region, Saudi Arabia, Asia, Europe and the Americas.

2. Background and Problem Statement

Global challenges in public health, agricultural applications and environmental management increasingly require alternatives to conventional chemical disinfectants and soil modifiers. The latter frequently induce resistance development, exhibit toxic properties, and cause ecological disturbances. In regions such as South-Eastern Europe and the MENA area, deficient hygiene infrastructure exacerbates the risk of nosocomial infections, while agronomic productivity is impaired by soil chemistry imbalances.

The decisive distinction from the state of the art: conventional electrochemically activated waters (EAW) such as acidic electrolysed water (AEW) or electrolysed reduced water (ERW) are obtained from dilute saline solutions by simple electrochemical dissociation. The liquid investigated within this research project, by contrast, is based on a biochemically controlled process that utilises a specially prepared source liquid – not an ordinary aqueous solution. This distinction is scientifically material and must not be obscured.

3. Scientific Background: Demarcation from Established Methods

3.1 Conventional Electrolysis Procedures and Their Limitations

Electrochemically activated waters are well documented in the scientific literature. Acidic electrolysed waters (pH 2.5–6.5, ORP ≥ 650 mV, HOCl-dominant) exert antimicrobial effects via oxidative damage to microbial membranes and protein denaturation. Electrolysed reduced waters (pH 8.5–11.5, H₂-enriched) are investigated with regard to antioxidant effects. These procedures are fundamentally established and the subject of numerous peer-reviewed publications.

Their known limitations include: limited storage stability of active species (in particular HOCl and molecular hydrogen H₂ are volatile), dependence on electrode quality and salt concentration, variability of efficacy under real-world application conditions, and restricted scalability for decentralised crisis scenarios.

3.2 The CIRAS Research Process: Conceptual Classification

The process investigated within this project shares with the approaches described above the oxidative-antimicrobial mode of action – but goes beyond these in terms of process management, source material and scientific concept.

Key distinguishing features from conventional electrolysis:

• The source liquid is not a conventional aqueous saline solution, but a specially prepared form that has been scientifically characterised over several years, the precise nature of which forms part of the protected research knowledge.
• The biochemical process management integrates parameters that play no role in standardised electrolytic procedures, including aspects that, according to the current state of research, also engage quantum mechanical interaction principles – a domain to which the CIRAS Center for Health devotes particular research attention.
• The result is a liquid with a broader antimicrobial spectrum of activity (bactericidal, virucidal, fungicidal) and, according to current research findings, superior stability properties compared to conventional EAW products.
• Toxicological safety and ecological neutrality – in particular with respect to groundwater and soil microbiota – constitute central design parameters of the process.

For reasons of quality assurance and to protect against improper imitation, detailed technical specifications, process parameters and application protocols are not published at this time. The CIRAS Institute expressly points out that the process is based on the precise interaction of several parameters, the isolated consideration of which may lead to inadequate or potentially problematic results.

4. Antimicrobial Mode of Action: Scientific Classification

The liquid under investigation exerts its antimicrobial effect through several complementary mechanisms which, in combination, extend the spectrum of activity beyond that of conventional disinfectants:

Protein Denaturation and Enzyme Inactivation
The substance is designed to irreversibly denature microbial protein structures and inactivate enzymatic systems. This mechanism operates independently of specific resistance pathways, as it acts at the physicochemical level rather than through biochemical interaction with defined target structures.

Membrane Destruction
Through the structural destruction of microbial membranes, the integrity of cellular organisms is permanently compromised. This mechanism is indifferent to antibiotic resistance – a significant advantage in the global fight against multidrug-resistant pathogens.

Virucidal Activity
Unlike many conventional disinfectants, the substance under investigation addresses both cellular microorganisms and viral particles. The inactivation of viral structures occurs via oxidative destruction of structural proteins and lipid membranes. This dual mode of action interrupts infection chains both in the clinical point-of-care setting and in the domestic environment.

Reduction of Resistance Development
Due to the physical-oxidative mechanism of action – as opposed to biochemically specific mechanisms – the development of resistance to this process is, according to current research findings, considerably more limited than with conventional chemical disinfectants. This represents a material advantage over established methods.

5. Environmental Profile and Sustainability

A central design objective of the process is its ecological compatibility. Current research findings indicate:

• Toxin-free operation without exposure to chemical agents of classical disinfectants
• Environmental neutrality during application and degradation
• Biodegradability of active components following reaction with organic material
• Reduced environmental impact, particularly with respect to groundwater and soil microbiota
• Scalable production concepts with decentralised application capabilities
• Low production costs, enabling use even in economically weaker regions

6. Container Concept for Crisis Deployment

A key component of the practical implementation is a mobile container concept. The first production units of this type are currently being manufactured. They enable the process to be applied directly on site in crisis areas, without the finished liquid having to be transported over long distances.

The liquid can be drawn directly from the container – for example, for cleaning buildings and interiors or for filling large-volume spray containers for wide-area application. The concept responds to a recurring experience in humanitarian operations: in acute crisis situations, it is not knowledge that is lacking but rapid availability on the ground.

7. Phased Implementation Model

Phase	Description	Key Activities	Duration	Milestones
Phase 1: Feasibility & Prototyping	Site assessment and biochemical modelling	Geospatial evaluation; process optimisation; in-vitro antimicrobial evaluations; economic viability calculations	Q1–Q2 2026 (6 months)	Validated prototypes; reference datasets
Phase 2: Assembly & Calibration	Procurement and empirical fine-tuning of process components	Procurement of specialised components; ecotoxicological analyses; physiological effect modelling; supply chain development	Q3 2026 (3 months)	Operational units; initial efficacy indices
Phase 3: Empirical Validation	Controlled trials in sectoral environments	Antimicrobial potency assays; agronomic investigations; market integration tests	Q4 2026 – Q2 2027 (9 months)	>1 million litres produced; statistical validation
Phase 4: Dissemination & Expansion	International distribution and long-term monitoring	Distribution infrastructure rollout; global partner integration; publication of scientific findings	2027–2030 (4 years)	6–7 million litres/year; replicable research frameworks

8. Resource Allocation

• Total budget: USD 7,000,000
• Funding source: To be defined
• Distribution: 35% Infrastructure (mobile units), 25% Health (biological assays), 20% Environment (ecological monitoring), 20% Economics (market development)
• Governance standards: CIRAS oversight in accordance with GAAP/IFRS

9. Evaluation, Reporting and Verification

Quarterly reports by the CIRAS Center for Health with sector-specific performance indicators. Annual independent examination. Final report December 2027 with complete dataset and statistical conclusions.

10. Intellectual Property and Knowledge Dissemination

Biochemical process designs and empirical data remain with the CIRAS Institute. Joint scientific publications will acknowledge CIRAS and cooperating partners and be disseminated via open-access platforms.

11. Project Leadership and Oversight

• Scientific lead: Dr. rer. nat. Uwe Häcker (CIRAS Center for Health)
• Institutional coordination: Lothar Hartmann (CIRAS IIGO – Technology & Finance)
• Operational implementation: Quantoc Global Management – FZCO
• Project start: 1 January 2026
• Project end (Phase 1): 31 December 2027; extension to 2030 for expansion phase